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Abstract  
People who use drugs in many contexts have limited access to opioid substitution therapy and 
HIV care. Service integration is one strategy identified to support increased access. We reviewed and 
synthesized literature exploring client and provider experiences of integrated opioid substitution 
therapy and HIV care to identify acceptable approaches to care delivery. We systematically reviewed 
qualitative literature. We searched nine bibliographic databases, supplemented by manual searches of 
reference lists of articles from the database search, relevant journals, conferences, key organizations 
and consultation with experts. Thematic synthesis was used to develop descriptive themes in client and 
provider experiences. The search yielded 11 articles for inclusion, along with 8 expert and policy reports. 
We identify five descriptive themes: the convenience and comprehensive nature of co-located care, 
contrasting care philosophies and their role in shaping integration, the limits to disclosure and 
communication between clients and providers, opioid substitution therapy enabling HIV care access and 
engagement, and health system challenges to delivering integrated services. The discussion explores 
how integrated opioid substitution therapy and HIV care needs to adapt to specific social conditions, 
rather than following universal approaches. We identify priorities for future research. Acceptable 
integrated opioid substitution therapy and HIV care for people who use drugs and providers is most 
likely through co-located care and relies upon attention to stigma, supportive relationships and client 
centred cultures of delivery. Further research is needed to understand experiences of integrated care, 
particularly delivery in low and middle income settings and models of care focused on community and 
non-clinic based delivery.   
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Background  
People who use drugs (PWUD) experience limited access to the comprehensive package of HIV 
care (WHO, UNODC, & UNAIDS, 2012) including Needle and Syringe Programmes (NSP), Anti-Retroviral 
Treatment (ART) and Opioid Substitution Therapies (OST) (Degenhardt et al., 2014; Mathers et al., 
2010). The impacts of limited access  is compounded by how delivery in combination has synergistic 
effects (Strathdee et al.). OST, such as methadone and buprenorphine, reduces injecting frequency and 
subsequent risk of HIV transmission (MacArthur et al., 2012) and promotes adherence to, and coverage 
of, ART (Reddon et al., 2014; Uhlmann et al., 2010) and supports improved ART outcomes (A. J. Low et 
al., 2016). Whilst addressing political, economic and social barriers to care access is necessary (Krüsi, 
Wood, Montaner, & Kerr, 2010; Wolfe, Carrieri, & Shepard, 2010) a priority at the level of service 
delivery is to support integration of OST within a comprehensive package of HIV care (Lambdin, 
Mbwambo, Josiah, & Bruce, 2015; WHO, 2014; WHO & UNODC, 2009). 
 
Whilst integration for OST and HIV care is widely promoted (Sylla, Bruce, Kamarulzaman, & 
Altice, 2007), there is a need to integrate clients and providers perspectives on how to organize and 
deliver care. Integration – combining service functions (Briggs & Garner, 2006) - can be realised with a 
range of strategies (WHO, 2008): e.g. delivery within a single clinic, referrals between sites, delivery 
within community or home settings, supported or not by outreach (Grenfell et al., 2012; Keats et al., 
2015; Kennedy et al., 2010; Lucas et al., 2006; Treloar & Rance, 2014; Uyei, Coetzee, Macinko, & 
Guttmacher, 2011). We have little understanding of what specific approaches to integrated care should 
be prioritized (Drainoni et al., 2014). 
 
We reviewed and synthesised qualitative research documenting PWUD and provider 
experiences of OST and HIV care to support the development of  appropriate and acceptable care 
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delivery and policy (Glenton, Lewin, & Gülmezoglu, 2016; Jones et al., 2014; Leidel, Wilson, McConigley, 
Boldy, & Girdler, 2015; Treloar & Rhodes, 2009; Tuthill, McGrath, & Young, 2014).  
 
Methods  
We systematically searched for qualitative literature and used a thematic synthesis approach 
(Jones et al., 2014; Thomas & Harden, 2008; Tso et al., 2016). Reflecting how service innovations may be 
documented in non-scientific literatures, we included policy and grey literatures and reports as a 
supplementary resource (Grenfell et al., 2013; 2010), in order to identify novel models of service 
delivery and contextualize and explore the main review findings.  
 
We searched nine academic databases (Medline, Embase, Global health, Social policy and 
practice, CINAHL Plus, Academic search premier, IBSS, the Web of science, and Scopus) in February 
2015. A record of the search is available in supplementary file 1. The generic process involved searching 
for the terms HIV AND OST AND experiences, along with synonyms. We searched back to 1995 to reflect 
the change in HIV care owing to the availability of ART. We manually identified additional articles by i) 
searching reference lists of included articles from the database search, ii) identifying citations of 
included papers, iii) consulting experts in the field, iv) reviewing relevant journals and v) searching the 
websites of key organisations and conferences.  
 
Articles were assessed for inclusion by two reviewers according to criteria of studies using 
qualitative methodologies, reporting experiences or preferences of people who use drugs or providers 
of integrated OST and HIV care (within which we included HIV prevention and treatment); see additional 
file 1 for further detail. For inclusion in the review or as supplementary expert and policy literature for 
parallel discussion, reviewers discussed whether selected articles met the following standards: i) use of, 
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and transparent presentation, of research methodology, ii) methodology is appropriate for the aims and 
objectives of the study. The included citations were assessed using CASP guidelines to support the 
interpretation of studies and assessment of confidence in findings (CASP, 2015).  
 
Themes were developed based on major findings in included papers (Thomas & Harden, 2008). 
The supplementary expert and policy literature was used to further explore and add depth to the 
themes. AG and MS initially read and open coded data under findings sections, with iterations of 
identified themes and emerging analyses distributed to the broader review group for comment. 
Descriptive themes were then fully coded and developed by AG around first (respondents) and second 
(citation author) order interpretations based on frequency across the data (Noyes & Lewin, 2011). The 
emerging analysis was then discussed across the group. Nvivo 10 software was used to manage the 
analysis.  
 
Each theme was documented by AG using the ‘Confidence in the Evidence from Reviews of 
Qualitative research’ (CERQual) approach (Lewin et al., 2015) (findings integrated in table 3).  
 
Results  
Figure 1 summarises the search. Eleven studies were included in the review (table 1). The 
majority of citations were from the USA (7), and then from China, India, Russia and Ukraine. All studies 
used interviews to generate qualitative data. Most papers were of medium quality; limitations focused 
on brief accounts of methods, in the context of published articles having word limit constraints.  The 
literature focused entirely on ‘fixed site’ care in clinics, hospitals or offices (primary or general 
practitioner oriented care), with care then organized around single providers, or teams, and also 
referrals between sites.  
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Table 2 lists the expert and policy literature that we use to contextualise the main themes in the 
review. This literature described more models of care. As well as clinic-located care there was care in 
community, home and prison settings. There was also a greater geographic diversity: India, Indonesia, 
Portugal, Tanzania, Ukraine and the USA were all a focus.  
 
In the synthesis of included citations we identified five descriptive themes in how PWUD and 
providers experience integrated OST and HIV care. Each theme is supplemented with a discussion of the 
expert and policy literature.  Table 3 summarises these findings, including the CERQual assessment. As 
we note above, and discuss below, most evidence is from North America shaping the generalizability of 
findings. For each theme we describe the range of experiences, noting in particular differences and 
overlaps between views of clients and providers.  
 
1 Convenient and comprehensive care through co-location  
Co-location of services within one site was described by clients and providers as supporting 
convenient and comprehensive care.  
 
Having care in one location allowed multiple health issues to be addressed at the same time 
(Drainoni et al., 2014; Egan et al., 2011; Korthuis et al., 2010): “for me having it in the same place worked 
out well. I can get everything right here in this one facility, without having to run over here and over 
there’’ (Client in Egan et al., 2011)  
 
Some clients still sought quicker, geographically closer or less demanding care. OST clients 
highlighted barriers that complicated attending even one facility: distance (Drainoni et al., 2014), the 
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timing of work (Lin, Cao, & Li, 2014) and for women the need to arrange child care (Morrow & Costello, 
2004). Counselling on HIV that was part of several programmes was also described as burdensome by 
some clients (Batchelder et al., 2013; Drainoni et al., 2014; Egan et al., 2011). 
 
The expert and policy literature had similar findings. Co-located care was linked to easier access 
and was highly valued (Curtis, 2009; Grenfell et al., 2012; Pangaea, 2014; Tobias, Drainoni, & McCree, 
2000). There were still challenges for some of travel to even one site (Curtis, 2009; Demchenko, Kozhan, 
Varban, & Kolomiets, 2014).  
 
2 Contrasting philosophies of care 
Differing treatment philosophies shaped preferences for the location and approach to care. 
Principles of harm reduction and client centredness were linked to HIV focused care and more favoured 
by clients and providers.  
 
Egan et al (2011), where OST was integrated within a HIV care oriented setting, report 
physicians preferring clinic based services for how they differed from the regulated and punitive 
approach of methadone; providers reported the same in Weiss et al (2011). Some clients welcomed this 
client centred and harm reduction oriented approach: “[my HIV provider] made me feel really 
comfortable knowing that if I… were to get off it [i.e. OST] and relapse, or whatever, that she could…you 
know, that she could start giving it to me again.” (Korthuis et al., 2010).  
 
A focus on abstinence in OST focused settings was linked to limit setting and sanctions (Strauss 
& Mino, 2011). Some clients didn’t like this approach: “One thing, you’re five minutes late they’ll shut 
 10 
 
the door right in your face.” (Korthuis et al., 2010), although some favoured it: “I need the structure and 
the consequences” (Drainoni et al., 2014).  
 
Similar themes were evident in the expert and policy literature. HIV care was again linked to 
harm reduction principles (Curtis, 2009) and client centred approaches (Demchenko et al., 2014; 
Grenfell et al., 2012), whilst OST was also described as restrictive (Curtis, 2009). Tobias et al (2000) 
reported a range of provider views: some linked successful care to a harm reduction approach that 
tolerates drug use, others an abstinence based approach with clear boundaries, and one provider a 
combination of both harm reduction and abstinence models as necessary.  
 
3 The challenges of discussing and disclosing HIV and drug use within integrated care 
Integrating OST and HIV care was challenged by clients being unable or unwilling to discuss and 
disclose HIV and drug use status; challenges of stigma were also recognized by providers.  
 
Some clients felt that discussing HIV in the context of OST was not necessary. Drainoni et al. 
(2014) summarise: “the participants almost universally did not feel that HIV risk reduction counselling 
was helpful or a necessary component of their treatment”. Providers of OST trying to support ART 
reported that “sometimes you were trying to give advice, and they [clients] were like ‘I know, I know!’ 
“(Lin et al., 2014).  
 
Some OST clients living with HIV were comfortable disclosing their status in care settings: ‘‘now 
they know I got [HIV], and it’s like nothing to them, you know what I mean.’’ (Egan et al., 2011). For 
others stigma and discrimination were a challenge. Directly observed approaches to integrated OST and 
ART were cited as problematic (Lin et al., 2014). A client reported stopping taking ART at the 
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“methadone window” owing to stigma and shame; the extra pills described as a “little sign” of HIV 
(Batchelder et al., 2013).  
 
Stigma and discrimination against drug use was cited less as a challenge. Weiss et al (2011) 
report a nurse in a site integrating OST within a HIV care focused clinic as saying of clients experiencing 
withdrawals: “I hate providing care to these kinds of patients”. Providers and clients reported how some 
referrals for ART from OST sites were not fulfilled as providers would not start people on ART out of 
beliefs they wouldn’t adhere (Chakrapani, Kamei, Kipgen, & Kh, 2013; Lin et al., 2014). 
 
The expert and policy literature reported similar findings. Inability or unwillingness to discuss or 
disclose HIV was again reported (Demchenko et al., 2014; van Laere et al., 2010). Bruce et al (2014) 
suggest that people confronting addiction may not at first feel able to also confront HIV (see also 
Demchenko et al., 2014). Fears of HIV stigma were overcome in one setting by involvement of outreach 
workers in facilitating referrals (Grenfell et al., 2012).  
 
4 Varying mechanisms for OST enabling HIV treatment  
In the context of integrated care, OST was described by clients as enabling people to access and 
maintain HIV treatment through a range of mechanisms.  
 
OST enabling time was described by clients as facilitating HIV care through helping them to 
“remember” to take medication (Egan et al 2011), and through allowing people to find “the time” for 
care rather than being focused on obtaining drugs and being on the street (Mimiaga et al., 2010; Sarang, 
Rhodes, & Sheon, 2013). As described by an OST client: “People who take street drugs are busy thinking 
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about where to get drugs, how to get drugs and do not have time to take ART. It happened to me before 
I started taking substitution therapy” (Mimiaga et al., 2010).  
 
OST also fostered motivation and hope, or “reinvestment” in life, and HIV treatment resulted 
from this: “if it wasn’t for suboxone, I think I’d be dead, truly. [    ]. It just changed a lot of things in my 
life. I can see clearly now there’s - as a matter of fact I start seeing hope for myself. And I start feeling I 
could fight [HIV], and there’s nothing that I can’t accomplish.” (Egan et al., 2011).  
 
This theme was little explored in the expert literature. Bruce et al (2014) note how OST 
provides “stability and well being” and so engagement in HIV care. Conversely, Grenfell et al 
(2012) report how OST limited HIV treatment engagement owing to fears of medication 
interactions.  
 
5 The health system context for integrated care 
Contextual health system factors were described by providers as shaping the potential for, and 
nature of, integrated care within clinics.  
 
Requirements that clients pay for HIV care limited integration within an OST setting (Lin et al., 
2014), and challenges in health insurance coverage for both areas of treatment were cited (Drainoni et 
al., 2014). Integrated care within one site ended when funding for vital staff finished (Strauss & Mino, 
2011).  
 
Ineffective referrals were linked to the absence of formal policy support (Chakrapani et al., 
2014). ART providers’ reluctance to accept referrals was also linked to specific, results-oriented 
 13 
 
management systems: “Patient mortality rate is one of their performance appraisal indexes, so they only 
want compliant patients, ‘good patients’.” (Lin et al., 2014)   
 
There was greater discussion of the role of context within the expert and policy literature. 
Funding and resource challenges were raised (Van laere et al., 2010; Curtis, 2009), poor coordination 
(Van Laere et al., 2010), as well as government regulations (Bruce et al., 2014), lack of political support 
(Van laere et al 2010), lack of awareness of OST efficacy by people using drugs limiting demand 
(Ambekar, Arumugam, Sharma, Raju, & Singh, 2014) and criminalization of people using drugs 
(Demchenko et al., 2014). Successful referrals were limited by bureaucratic obstacles, but facilitated by 
informal professional networks (Grenfell et al., 2012); similarly, case management was seen as a way to 
overcome lack of communication across a health system (Tobias et al., 2000). Detailed strategies were 
suggested to manage contextual limitations (Bruce et al., 2014).  
 
Discussion 
This review has synthesized qualitative literature on client and provider experiences of 
integrated OST and HIV care. We found that co-located care is valued by clients for its convenience, 
although convenience is not experienced the same by all; HIV and OST focused settings are associated 
with different treatment philosophies with clients and providers having greater preference for the 
patient centred philosophies associated with HIV focused sites and care;  stigma limits the potential for 
co-located care, especially when delivered through directly observed approaches; and specific health 
system barriers shape the possibilities for integrated care. We discuss these findings to develop 
recommendations.  
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A strong theme was the support for the co-location of care within one facility for how it 
facilitates comprehensive and convenient care. This co-location of care should be favoured over referral 
models . There are however limits to this convenience and it is also experienced differently: women may 
face greater hurdles to care access and these varying needs should be explored (Azim, Bontell, & 
Strathdee, 2015; Deshko, 2015).  
In planning and developing integrated services HIV and drug stigma should be a primary 
consideration. Co-located care especially poses challenges in terms of stigma (Beyrer et al., 2011), 
particularly with directly observed approaches to care through ‘methadone windows’ (Bourgois, 2000; 
Crawford, 2013; Fraser, 2006).  Co-located care should therefore be prioritized only if attention is paid 
to the need for privacy and confidentiality (Beyrer et al., 2011). This could include support to providers 
and adapting delivery settings, or ‘co-locating’ care within community settings (Grenfell et al., 2012)). If 
such approaches to addressing stigma are not feasible or ineffective, then alternative – potentially 
additional – care models should be prioritized. For example, support to effective referral pathways 
between facilities, through facilitating outreach support (Broadhead et al., 1998; Keats et al., 2015; 
Treloar et al., 2015).  
 
The review indicates HIV care oriented settings have a greater orientation to client centred 
practices (Daftary, Calzavara, & Padayatchi, 2015) and  may  be better suited to integrating OST focused 
on achieving HIV prevention and treatment goals. Client centred practices that allow for harm reduction 
focused low threshold care (Strike, Millson, Hopkins, & Smith, 2013) would have long term retention in 
OST – and in turn HIV treatment and prevention - as a primary goal. OST settings that may more 
commonly emphasize abstinence may be experienced as restrictive or punitive (Bourgois, 2000) and in 
so doing place less priority on retention in care, and so HIV treatment. However, a sole focus on HIV care 
settings for OST integration would limit some clients’ preference for abstinence focused care and also 
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challenges of existing clinic infrastructures. Integrated care may then be best served by prioritizing 
‘integration’ of treatment philosophies (Daftary et al., 2015). A client centred philosophy that is flexible 
to the needs of individuals (Islam, Topp, Day, Dawson, & Conigrave, 2012) could be the focus for 
synthesizing delivery cultures of both harm reduction and abstinence strategies within both HIV and OST 
oriented settings, depending on collaborative decisions over care between providers and clients (Harris 
& Rhodes, 2012; McKeganey, 2011; Rance & Treloar, 2015).  
 
Health system policies and contexts were described as influencing integrating care, although the 
literature was varied and referred to a range of barriers. These findings come in the context of 
considerable evidence for the need for increased funding for harm reduction and care for PWUD (HRI, 
IDPC, & Alliance, 2014)and recognition of the structural barriers to separate OST and HIV care , such as 
the legality of OST, bureaucratic demands and the broader criminalization and persecution of PWUD 
(Bojko et al., 2015; Rhodes & Sarang, 2012). The expert and policy literature brought more insight to the 
role of context, and suggested directions for managing these barriers. Whilst more documentation of 
these health system barriers and responses to them is needed, the available policy literature and 
broader evidence supports the need for policy change to create supportive contexts.  
 
The limited empirical literature found indicates the need to document existing models of care 
and experiences of access. A specific methodological opportunity is greater use of mixed-methods 
approaches to study the integration of care. There is considerable quantitative study of  OST and HIV 
care (A. Low et al.), but little use of qualitative methods to document care processes and models that 
form the context for clinical outcomes (e.g. Conway et al., 2004; Lucas, Weidle, Hader, & Moore, 2004). 
Documenting experiences of care in low and middle income settings is a priority, as well as focusing 
more on how gender shapes access. 
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The expert and policy literature described a greater diversity of care models, drawing attention 
to the potential for home and community focused delivery, peer and outreach support. Greater 
consideration should be given to developing these care models linked to rigorous monitoring and 
evaluation.  
 
The literature identified important themes, although was limited in depth, even if the number of 
papers cited compares to other similar reviews (Leidel et al., 2015; Thomas & Harden, 2008). The 
exclusion of non-English language literature may also have limited the depth of the data. We have 
sought to manage these limitations through including expert and policy literatures to explore and 
expand on the empirical evidence The thematic synthesis approach used also faces limitations, 
particularly through how individual findings are decontextualized within themes (Thomas & Harden, 
2008); the approach does however serve the policy oriented purpose of giving insight to significant 
experiences and to questions of care need and appropriateness across diverse contexts (Ring, Ritchie, 
Mandava, & Jepson, 2011).  
 
Conclusions  
These findings complement existing calls for integration of OST and HIV care (Sylla et al) by 
providing clarity on PWUD and provider views on care. Priority considerations for developing care 
include: emphasising co-located integrated care, attention to stigma and the need to synthesize 
treatment philosophies around client centred care. More research is needed to understand a greater 
range of care models and how contextual factors shape experiences of integration.  
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Table 1. Citations included in the review 
 
Title  Countr
y 
Aim  Study methods Population Integrated care 
model 
1 Batchelder 
et al. (2013).  
USA To understand 
HIV treatment 
adherence 
experiences 
amongst people 
using methadone 
as a maintenance 
therapy  
In-depth 
interviews with 
participants in a 
clinic based trial 
of an 
intervention  
People living 
with HIV 
(PLHIV) 
accessing 
methadone, 
n=15 (5 
women, 
10men) 
Directly Observed 
Therapy (DOT) 
approach to  ART 
in a methadone 
clinic  
2 
Chakrapani, 
et al. (2014).  
India To understand 
barriers to HIV 
treatment access 
in government 
run ART centres  
Focus groups 
with PWID and 
key informant 
interviews 
PLHIV, n = 19, 
all men, 4 on 
ART. Number 
on OST not 
specified. 
Interviews 
with 2 
physicians and 
2 heads of 
community 
agencies  
OST available by 
referral from HIV 
treatment and care 
clinics.  
3  
Drainoni, M. 
et al. (2014).  
USA To evaluate a 
team based 
model of 
Focus groups 
with clients  
and open 
40 
intervention 
clients in focus 
Primary care 
integrated mode of 
substance use 
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Title  Countr
y 
Aim  Study methods Population Integrated care 
model 
integrated OST 
and HIV care 
within a primary 
care site  
responses as 
part of 
satisfaction 
surveys  
groups, 212 in 
open response 
survey; 65% 
receiving 
buprenorphin
e/naloxone 
(no 
breakdown by 
gender given) 
treatment and 
medical care, 
including 
buprenorphine/nal
oxone and HIV risk 
reduction 
counselling  
4  
Egan, et al. 
(2011). 
USA To describe 
patient 
experiences of 
buprenorphine/n
aloxone 
treatment and its 
integration in to 
HIV care settings  
Semi-structured 
interviews  
33 PLHIV (22 
men, 11 
women) 
enrolled at 
integrated 
delivery sites 
from across 
USA  
‘Office based’ 
[primary care] 
delivery of OST and 
HIV care 
5  
Korthuis, et 
al. (2010).  
USA To explore PLHIV 
attitudes towards 
OST in ‘office 
based’ integrated 
care settings (that 
include HIV care) 
in comparison to 
In-depth 
interviews  
29 PLHIV all 
receiving 
buprenorphin
e (23 men, 6 
women) 
Context of 
randomized trial of 
two OST delivery 
strategies (office 
based integration 
with HIV care, OST 
setting)  
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Title  Countr
y 
Aim  Study methods Population Integrated care 
model 
exclusively OST 
settings, and then 
how this 
influences HIV 
care  
6  
Lin, C., et al. 
(2014). 
China  To evaluate pilot 
of ART integration 
within 
methadone clinics 
Focus groups 12 OST service 
providers from 
6 clinics  
On-going ART 
delivery within 
methadone clinics 
through directly 
observed 
approaches (ART 
initiation in 
separate sites) 
7  
Mimiaga, et 
al. (2010).  
Ukrain
e  
To explore 
barriers and 
facilitators to ART 
adherence for 
PWID in Ukraine  
Focus groups  16 PLHIV 
(11men,5 
women) 
attending an 
AIDS care 
centre, 14 of 
whom on OST  
OST co-located 
within same 
building as HIV 
care centre  
8  
Morrow and 
Costello 
(2004).  
USA To assess needs 
and women’s 
preferences for  
Qualitative 
study to inform 
quantitative 
survey: focus 
30 women 
using 
methadone 
(10 in focus 
Context of 
methadone 
delivery (no 
specific integration 
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Title  Countr
y 
Aim  Study methods Population Integrated care 
model 
HIV/STI and 
hepatitis 
prevention within  
methadone 
delivery 
groups, dyad 
interviews and 
in-depth 
interviews  
groups, 4 in 
dyad 
interviews, 16 
in interviews) 
care pathway 
described)  
9  
Sarang, et 
al. (2013).  
Russia To explore 
barriers to HIV 
treatment access 
among PWUD 
Qualitative in-
depth 
interviews  
42 PLHIV (26 
men, 16 
women) none 
on OST  
No integrated care 
pathway available  
10 
Strauss, and 
Mino 
(2011).  
USA  To identify 
implementation 
barriers to 
combined 
substance use 
treatment and 
HIV care  
Semi-structured 
interviews with 
staff 
Staff of 
substance use 
treatment 
programmes 
(n not 
specified) 
Integration of HIV 
care in to 
substance use 
treatment 
programmes 
focused on 
methadone 
delivery, linked to 
maintenance or 
abstinence focused 
care 
11 
Weiss, et al. 
(2011).  
USA To evaluate the 
process of 
integrated OST 
Semi-structured 
interviews  
10 site 
principal 
investigators, 
who led 
Buprenorphine 
within HIV care at 
hospital, 
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Title  Countr
y 
Aim  Study methods Population Integrated care 
model 
within HIV clinical 
care  
implementatio
n of new 
services  
community or HIV 
care centres  
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Table 2. Expert experiences and policy literature 
Citation  Country Report aim or 
focus  
Report 
design or 
approach 
Population Integrated 
care model 
1 Ambekar,  
et al. (2014).  
India  Survey of 
experiences of 
PWUD in drug 
use and service 
access 
Structured 
interviews 
with PWUD 
1000 PWUD 
across 22 sites 
Context for 
survey of 
‘Targeted 
Interventions’ 
for PWUD; 
centres that 
include OST, 
NSP and link 
to HIV care 
2 Bruce, et 
al. 2014  
Tanzania  Reflections on 
lessons learned 
through 
implementing 
integrated OST 
and HIV care 
No particular 
design; 
report by 
programme 
team  
12 member 
team engaged 
in delivery or 
development 
of the services  
MAT site in 
Tanzania, with 
integrated HIV 
care: ART daily 
dosing 
alongside 
observed MAT 
3 Curtis. 
(2009).  
Ukraine WHO 
commissioned 
short report of 
case studies of 
integration  
No particular 
design; 
author led 
consultation 
and 
observations  
Various 
providers and 
service clients 
across 
multiple 
Various sites in 
Ukraine: one 
site of 
referrals 
between 
clinics; MAT 
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Citation  Country Report aim or 
focus  
Report 
design or 
approach 
Population Integrated 
care model 
service sites (n 
not specified). 
site in a 
hospital linked 
to other 
clinics; co-
location of 
services within 
an HIV focused 
site  
4 
Demchenko, 
et al. (2014).  
Ukraine  Evaluation of 
service access 
for PWUD 
Semi-
structured 
interviews 
and focus 
groups with 
clients, in-
depth 
interviews 
with 
providers 
500 clients of 
OST 
Various sites in 
Ukraine 
5 Grenfell et 
al (2012)  
Portugal Rapid 
assessment to 
assess 
acceptability and 
integration of 
Mixed-
methods 
rapid 
assessment 
including 
30 PWID (3 
women, 27 
men; 26 
PLHIV, and 21 
currently on 
Two models 
documented: 
i) all services 
available 
within a single 
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Citation  Country Report aim or 
focus  
Report 
design or 
approach 
Population Integrated 
care model 
HIV, TB and drug 
dependency 
treatment 
(including OST) 
in Portugal 
mapping, 
analysis of 
secondary 
data and 
interviews 
with PWID 
and providers 
treatment; 26 
had 
experienced 
OST, 24 
currently)  
7 providers 
engaged in 
HIV, TB and 
OST care 
centre, ii) 
services 
available 
through 
referral 
between 
separate 
facilities, 
supported by 
outreach 
teams  
6 Van Laere, 
et al. (2010).  
Indonesia Baseline 
evaluation of 
services in six 
methadone 
clinics  
Mixed 
methods 
evaluation, 
including 
interviews 
with 
providers, 
and focus 
groups  
Providers, n 
not stated  
MAT clinics 
with varying 
levels of on-
site 
integration of 
HIV care: HIV 
prevention 
(condoms, 
NSP), VCT. ART 
only by 
referral to HIV 
clinics. 
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Citation  Country Report aim or 
focus  
Report 
design or 
approach 
Population Integrated 
care model 
7 Tobias, et 
al. (2000).  
USA Information 
review on 
delivery of HIV 
services for 
people using 
drugs  
Literature 
review and 
key 
informant 
interviews  
50 key 
informants 
(providers, 
community 
leaders, 
government 
staff, 
researchers) 
Not applicable 
8 Pangaea 
Global AIDS 
Foundation. 
2014  
Global  Expert 
consultation on 
appropriate 
models of 
integrated HIV 
care for PWID in 
Africa  
Expert 
perspectives 
and reports 
on 
programme 
experience  
Stakeholders, 
including 
providers 
Various  
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Table 3. Summary of review findings and CERQUAL assessment  
Theme Included citations  CERQual 
assessment of 
confidence in the 
evidence 
Explanation of 
CERQual 
assessment 
1 Convenient and comprehensive OST and HIV care 
through co-located integrated care 
Having OST and HIV care available at one site, whether 
through a single provider or team of providers, was 
welcomed by clients as convenient and facilitating 
attention to multiple health priorities. There are still 
limitations described, with access to a single facility 
itself posing challenges of time and transport. 
Drainoni et al 2014, 
Egan et al 2011, 
Korthuis et al 2010, 
Lin et al 2014, 
Morrow & Costello 
2004, Weiss et al 
2011 
High/moderate 
High 
methodology 
quality, high 
relevance, and 
high coherence, 
although thin 
data and narrow 
range of 
countries 
represented. 
2 Contrasting philosophies of care Integrated care 
varied according to different philosophies, centred on 
harm reduction or sobriety, with clients having 
different preferences shaped by their experiences and 
goals for OST. 
Drainoni et al 2014, 
Egan et al 2011, 
Korthuis et al 2010, 
Strauss & Mino 2011, 
Weiss et al 2011 
moderate 
High relevance, 
but only 
moderate 
methodological 
quality and 
coherence, with 
low range of 
countries. 
3 The challenges of discussing and disclosing HIV and 
drug use Whilst some reported comfort and willingness 
to disclosure and discuss HIV status, some found this 
difficult because of stigma and fears of discrimination, 
or not considering it necessary to address HIV in OST 
settings 
Batchelder et al 
2013, Drainoni et al 
2014, Egan et al 
2011, Korthuis et al 
2010, Lin et al 2014 
moderate 
High relevance, 
but moderate 
quality, and low 
coherence and 
range of 
countries  
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4 OST enabling HIV treatment OST facilitates 
overcoming social and structural barriers to addressing 
HIV for some people, through varying mechanisms 
Egan et al 2011, 
Korthuis et al 2010, 
Mimiaga et al 2010, 
Sarang et al 2013, 
Weiss et al 2011 
low 
Moderate quality 
and relevance, 
but low 
coherence and 
low range of 
countries 
5 The health system context for integrated care 
Contextual policy and system issues shape the potential 
for, and nature of, integration 
Chakrapani et al 
2014, Drainoni et al 
2014, Lin et al 2014, 
Strauss & Mino 2011, 
Weiss et al 2011 
Moderate/low 
High relevance, 
but moderate 
quality and low 
coherence and 
adequacy 
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